Genelux Corporation (GNLX)
Develops modified viruses that attack cancer tumors while boosting the immune system.
$2.92-0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-16.8%
The outlook
GNLX is trading near its 52-week lows and below both its 50- and 200-day moving averages, reflecting a weak near-term trend. Analyst coverage shows a wide disconnect—the average price target sits roughly five times the current price, though the overall StockGlow score leans bearish. The stock remains a speculative position with limited upside momentum visible in current technicals.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range10% of the way from its 52-week low to high
Price targetAvg target +499% vs current price
Analyst price target
~12-month · 6 analysts$17.50average target+499.3% vs now
Now $2.92
Low $10.00High $31.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$130.9M
52-wk high
$8.54
52-wk low
$2.29
50-day avg
$2.94
200-day avg
$3.58
Trailing P/E
—